September/October 2009, Vol 2, No 6
It wasn't supposed to happen this way. The 1000-page House of Representatives healthcare reform bill, "America's Affordable Health Choices Act," was supposed to follow the new Congressional passage sequence: distribute it to all the usual suspects, read it on the cab ride to the hotel, and immediately sign it into law. So when Congressional members on both sides of the aisle started boring into the draft of the bill and came back with concern over language that only suggested a troubling threat to seniors, political veterans were caught off guard.
With cost becoming a major obstacle in any potential healthcare reform, the role of generic drugs is gaining even greater popularity than before among policymakers as a cost-saving feature in the attempt to overhaul our healthcare system. The tension between the makers of generic drugs and brandname manufacturers notwithstanding, there is a general agreement in government that increased use of generics can substantially reduce overall healthcare costs, especially during the current economic environment.
The decision-making process in many aspects of the healthcare delivery system is often complicated and detailed, requiring many considerations before arriving at a course of action in patient care. Increasingly today, the perspectives of each healthcare stakeholder should be considered, which often leads to confusion and controversy in decisionmaking. For example, what is of value to a patient may not be of value to a provider, and what medical evidence determines to be of value may be very limited or subject to interpretation because of the paucity of definitive evidence.
Potential Benefits of Prediction Models from Large Electronic Databases
Estimates of Commercial Population at High Risk for Cardiovascular Events: Impact of Aggressive Cholesterol Reduction
Kathryn Fitch, RN, MEd, Sara W. Goldberg, FSA, MAAA, Kosuke Iwasaki, FIAJ, MAAA, Bruce Pyenson, FSA, MAAA, Andreas Kuznik, PhD, Henry A. Solomon, FACP, FACC
Impact of Prescription Benefit Coverage Limits on Sevelamer Hydrochloride Adherence for Patients with ESRD
Hyperphosphatemia is prevalent among patients with end-stage renal disease (ESRD) and continues to be an important and challenging area for drug therapy.
Balancing Horizontal and Vertical Equity within Managed Health Plans Drug Benefit
Nancy M. McGee, JD, MPH, Gene Reeder, RPh, PhD, Timothy S. Regan, BPharm, RPh, CPh, J.D. Kleinke, Steve Arnold, MD, MS, MBA, CPE
Across socioeconomic strata, American households are adopting an increasingly electronic way of life. Bills are routinely paid online, bank balances are tracked, goods are purchased, and music is downloaded at record consumer adoption rates.1 Income levels, bank balances, and consumer preferences are routinely shared and stored in the electronic ether. There is a unity of confidence and comfort on behalf of the consumer and the vendor that these personal pieces of information are safe and secure.
Electronic PHRs and e-Prescribing: Not Quite There Yet
Results 1 - 7 of 7